Alnylam Pharmaceuticals Inc.


Alnylam Reports Positive Interim Results From Phase 1 Study Of ALN-AGT

RNAi therapeutics company Alnylam Pharmaceuticals Inc reported positive interim data from its ongoing Phase 1 study of ALN-AGT. The company is evaluating ALN-AGT …

3 Monster Growth Stocks That Can Climb Higher as Market Plunges

Markets are plunging, taking a serious hit as the coronavirus spreads rapidly throughout the world. So far, the worst of the outbreak is …

Alnylam Pharmaceuticals, Inc. (ALNY) Picks Up a Price Target Boost from Cowen Following Stellar Phase III Top-Line Data in FAP

Analyst praises Alnylam’s patisiran as best-in-class, even more confident in its safety and tolerability profile.

Notable Analyst Rating Changes: Tesla Motors Inc (TSLA), Alnylam Pharmaceuticals, Inc. (ALNY)

Tesla Motors Inc Tesla Motors Inc (NASDAQ:TSLA) shares dropped nearly 4% today after Goldman Sachs analyst David Tamberrino downgraded the electric car giant from Buy to …

Analysts Weigh in on Volatile Biotech Stocks: Alnylam Pharmaceuticals, Inc. (ALNY) and Aurinia Pharmaceuticals (AUPH)

Analysts offer insights into a volatile biotech-verse amid Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares dipping on news of a program termination and Aurinia Pharmaceuticals (NASDAQ:AUPH) soaring on …

Stock Update (NASDAQ:ALNY): Here’s Why Alnylam Pharmaceuticals, Inc. Shares Are Dropping 45%

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) investors are having a rough morning after the RNAi therapeutics company announced that it has decided to discontinue development of revusiran, an …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts